Category
Policy
Scheduling, legislation, and public funding decisions shaping where and how ibogaine research can move forward.
Kentucky's bid to fund ibogaine research with opioid settlement money stalls
A 2023 proposal to direct $42 million in opioid settlement funds toward an ibogaine clinical trial was withdrawn after leadership changes at the commission overseeing the allocation.
MH
Margaret Holcombe8 min readWhat an FDA breakthrough therapy designation would and would not change
Advocates have called for the FDA to grant ibogaine breakthrough therapy status. The designation would accelerate review timelines but would not itself resolve the underlying evidentiary questions.
MH
Margaret Holcombe7 min read